Edition:
United Kingdom

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

3.94EUR
4:35pm BST
Change (% chg)

€0.05 (+1.16%)
Prev Close
€3.89
Open
€3.93
Day's High
€3.99
Day's Low
€3.90
Volume
100,731
Avg. Vol
221,160
52-wk High
€5.20
52-wk Low
€2.89

Chart for

About

MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis... (more)

Overall

Beta: 1.05
Market Cap(Mil.): €233.70
Shares Outstanding(Mil.): 59.94
Dividend: --
Yield (%): --

Financials

  MDXH.BR Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.21 -- --
ROI: -24.45 -7.38 12.74
ROE: -25.52 -10.11 14.64

BRIEF-MDxHealth Announces Positive Clinical Updates For ConfirmMDx

* REG-MDXHEALTH ANNOUNCES POSITIVE CLINICAL UPDATES FOR CONFIRMMDX

26 Apr 2018

BRIEF-Mdxhealth Q1 Operating Loss widens to 6.7 Million Dollars

* Q1 TOTAL REVENUE OF $9.7 MILLION, UP 50% FROM $6.5 MILLION IN Q1 2017

24 Apr 2018

BRIEF-Mdxhealth: Inclusion Of Selectmdx In Dutch Diagnosis Related Groups Reimbursement System

* INCLUSION OF SELECTMDX FOR PROSTATE CANCER IN DUTCH DIAGNOSIS RELATED GROUPS (DRG) REIMBURSEMENT SYSTEM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Apr 2018

BRIEF-3D Signatures Signed Collaboration Agreement With Mdxhealth SA To Evaluate Co's Prognostic Test Candidate For Prostate Cancer

* 3D SIGNATURES - SIGNED COLLABORATION AGREEMENT WITH MDXHEALTH SA TO EVALUATE CO'S PROGNOSTIC TEST CANDIDATE FOR PROSTATE CANCER

28 Mar 2018

BRIEF-Bookrunner On MDxHealth Books Says Accelerated Bookbuilding Of Offering Of Up To 9.9 Million

* BLOCK TRADE : MDXHEALTH SA - BOOKRUNNER SAYS ACCELERATED BOOKBUILDING OF OFFERING OF UP TO 9.9 MILLION NEW SHARES OR UP TO ABOUT 20 PERCENT OF CURRENT SHARE CAPITAL

21 Mar 2018

BRIEF-MDxHealth Says SelectMDx Liquid Biopsy Test In 2018 European Association Urology Guidelines

* REG-MDXHEALTH (R): SELECTMDX LIQUID BIOPSY TEST FOR PROSTATE CANCER INCLUDED IN THE 2018 EUROPEAN ASSOCIATION UROLOGY GUIDELINES

19 Mar 2018

BRIEF-Mdx Pcl Posts Fy Net Profit Of 221 Mln Baht

* FY TOTAL REVENUES 267.1 MILLION BAHT VERSUS 241.2 MILLION BAHT

02 Mar 2018

BRIEF-Mdxhealth Contract Selectmdx With Roman Hospital

* ‍MDXHEALTH ENTERS INTO COMMERCIAL AGREEMENT FOR SELECTMDX WITH FONDAZIONE LUIGI MARIA MONTI - ISTITUTO DERMOPATICO DELL' IMMACOLATA HOSPITAL IN ROME​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

28 Feb 2018

BRIEF-Mdxhealth FY Total Revenue Up 35 pct at 40 Million Dollars

* FY TOTAL REVENUE OF $40 MILLION UP 35% WITH CONTINUED STRONG VOLUME GROWTH

22 Feb 2018

BRIEF-MDxHealth ‍Develops Blood Test For Prostate Cancer Patients​

* ‍DEVELOPS BLOOD TEST TO GUIDE PRECISION-TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS​

18 Jan 2018

Earnings vs. Estimates